Personalized mRNA Cancer Vaccines Hit a Historic Milestone as Breakthrough Treatments Proliferate

Merck and Moderna just pulled off a first for cancer medicine. Their personalized mRNA cancer vaccine, intismeran, met both primary and secondary goals in a Phase 3 trial of 1,137 high-risk melanoma patients — making it the first positive late-stage result for any mRNA cancer vaccine. The treatment combines Moderna's made-to-order vaccine (crafted from mutations in each patient's own tumor) with Merck's blockbuster immunotherapy Keytruda. Patients who got the combo saw reduced...